CN110732016A - A topical essential oil of fructus Cinnamomi Immaturus for treating dysmenorrhea - Google Patents
A topical essential oil of fructus Cinnamomi Immaturus for treating dysmenorrhea Download PDFInfo
- Publication number
- CN110732016A CN110732016A CN201911275190.7A CN201911275190A CN110732016A CN 110732016 A CN110732016 A CN 110732016A CN 201911275190 A CN201911275190 A CN 201911275190A CN 110732016 A CN110732016 A CN 110732016A
- Authority
- CN
- China
- Prior art keywords
- essential oil
- cinnamon
- prepared
- fennel
- angelica
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000341 volatile oil Substances 0.000 title claims abstract description 112
- 206010013935 Dysmenorrhoea Diseases 0.000 title claims abstract description 28
- 208000005171 Dysmenorrhea Diseases 0.000 title claims abstract description 26
- 230000000699 topical effect Effects 0.000 title description 2
- 235000017803 cinnamon Nutrition 0.000 claims abstract description 29
- 239000003814 drug Substances 0.000 claims abstract description 21
- 240000006927 Foeniculum vulgare Species 0.000 claims abstract description 17
- 235000004204 Foeniculum vulgare Nutrition 0.000 claims abstract description 17
- 244000061520 Angelica archangelica Species 0.000 claims abstract description 15
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 15
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 12
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940116229 borneol Drugs 0.000 claims abstract description 12
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 12
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 238000002156 mixing Methods 0.000 claims abstract description 6
- 238000000605 extraction Methods 0.000 claims description 49
- 241000723347 Cinnamomum Species 0.000 claims description 26
- 238000000926 separation method Methods 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 16
- 239000000463 material Substances 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 13
- 239000000843 powder Substances 0.000 claims description 13
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 11
- 235000008397 ginger Nutrition 0.000 claims description 11
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 8
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 8
- 235000021511 Cinnamomum cassia Nutrition 0.000 claims description 8
- 241001078983 Tetradium ruticarpum Species 0.000 claims description 8
- 244000150195 Cyperus longus Species 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 3
- 244000273928 Zingiber officinale Species 0.000 claims 2
- 235000018109 Cyperus longus Nutrition 0.000 claims 1
- 244000075634 Cyperus rotundus Species 0.000 claims 1
- 235000005010 Scirpus paludosus Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 11
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 3
- 240000006766 Cornus mas Species 0.000 abstract 2
- 208000002193 Pain Diseases 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 12
- 230000005906 menstruation Effects 0.000 description 11
- 241000234314 Zingiber Species 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 6
- 241000209020 Cornus Species 0.000 description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 4
- 101800000989 Oxytocin Proteins 0.000 description 4
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 229960002986 dinoprostone Drugs 0.000 description 4
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 4
- 229960001723 oxytocin Drugs 0.000 description 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 3
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 3
- 240000007890 Leonurus cardiaca Species 0.000 description 3
- 235000000802 Leonurus cardiaca ssp. villosus Nutrition 0.000 description 3
- 229950002007 estradiol benzoate Drugs 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 206010000084 Abdominal pain lower Diseases 0.000 description 2
- 201000000736 Amenorrhea Diseases 0.000 description 2
- 206010001928 Amenorrhoea Diseases 0.000 description 2
- 101000692466 Bos taurus Prostaglandin F synthase 2 Proteins 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 231100000540 amenorrhea Toxicity 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- PXGPLTODNUVGFL-UHFFFAOYSA-N prostaglandin F2alpha Natural products CCCCCC(O)C=CC1C(O)CC(O)C1CC=CCCCC(O)=O PXGPLTODNUVGFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000005641 Adenomyosis Diseases 0.000 description 1
- 241000382455 Angelica sinensis Species 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 206010019909 Hernia Diseases 0.000 description 1
- 208000037093 Menstruation Disturbances Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 244000242564 Osmanthus fragrans Species 0.000 description 1
- 235000019083 Osmanthus fragrans Nutrition 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010058674 Pelvic Infection Diseases 0.000 description 1
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 238000011278 co-treatment Methods 0.000 description 1
- 235000021270 cold food Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- XNOPRXBHLZRZKH-MQYCRUOZSA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1C(CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-MQYCRUOZSA-N 0.000 description 1
- 229940082408 oxytocin injection Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/235—Foeniculum (fennel)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/37—Extraction at elevated pressure or temperature, e.g. pressurized solvent extraction [PSE], supercritical carbon dioxide extraction or subcritical water extraction
Abstract
The invention relates to external cinnamon and dogwood essential oil for treating dysmenorrhea, which can effectively solve the problem of drug use for treating dysmenorrhea and adopts the technical scheme that the external cinnamon and dogwood essential oil comprises the following raw materials: 5-7mL of cinnamon essential oil, 5-7mL of fructus evodiae essential oil, 5-7mL of rhizoma zingiberis essential oil, 4-6mL of angelica essential oil, 5-7mL of rhizoma cyperi essential oil, 4-6mL of fennel essential oil and 5-7g of borneol, and the traditional Chinese medicine is prepared by dissolving and uniformly mixing; the invention has the advantages of rich raw materials, scientific and reasonable matching, simple preparation method, easy production and manufacture, good product quality, stable and reliable curative effect and remarkable economic and social benefits.
Description
Technical Field
The invention relates to a medicine, in particular to external-use cinnamon twig and dogwood essential oil for treating dysmenorrhea.
Background
Dysmenorrhea (dysmenorrha) is , the most common gynecological symptom, which refers to lower abdominal pain and swelling before and after menstruation or during menstruation with waist soreness or other discomfort, and the symptom seriously affects the quality of life, usually occurs in adolescence within 1-2 years after initial tide, lower abdominal pain with regular menstrual cycle attack is the main symptom, the first 12 hours before menstruation occurs, the most severe pain in the 1 st day of menstruation is continuously relieved after 2-3 days, the pain is usually spastic, is not accompanied by abdominal muscle tension or rebound pain, the treatment mainly aims at symptomatic treatment, pain is mainly relieved and calmed, although various medicines for treating dysmenorrhea exist, the use and curative effect are not satisfactory for various reasons, and therefore, the provision of new medicines for treating dysmenorrhea is a technical problem to be seriously solved.
Disclosure of Invention
Aiming at the situation, in order to overcome the defects of the prior art, the invention aims to provide cinnamon and dogwood essential oil for treating dysmenorrhea by external use, which can effectively solve the problem of medication for treating dysmenorrhea.
The technical scheme includes that external-use cinnamomum cassia presl essential oil for treating dysmenorrhea is prepared by dissolving and uniformly mixing 5-7mL of cinnamomum cassia presl essential oil, 5-7mL of evodia rutaecarpa essential oil, 5-7mL of dried ginger essential oil, 4-6mL of angelica sinensis essential oil, 5-7mL of nutgrass galingale rhizome essential oil, 4-6mL of fennel essential oil and 5-7g of borneol, wherein:
the cinnamon essential oil is prepared by crushing cinnamon into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Extracting a fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the weight-volume ratio refers to that the solid is counted by g, the liquid is counted by mL, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain cinnamon essential oil;
the fructus evodiae essential oil is prepared by crushing fructus evodiae into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the evodia rutaecarpa essential oil;
the dried ginger essential oil is prepared by crushing dried ginger into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the dried ginger essential oil;
4ml of angelica essential oil is prepared by crushing angelica into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃,the separation pressure is 4.5-5.5 MPa, the extraction time is 1.5-2.5 h, and the angelica essential oil is obtained;
the rhizoma cyperi essential oil is prepared by crushing rhizoma cyperi into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the nutgrass galingale rhizome essential oil;
the fennel essential oil is prepared by crushing fennel into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2And (3) fluid extraction, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the fennel essential oil is obtained.
The borneol is the borneol conforming to Chinese pharmacopoeia.
The invention has the advantages of rich raw materials, scientific and reasonable matching, simple preparation method, easy production and manufacture, good product quality, stable and reliable curative effect and remarkable economic and social benefits.
Detailed Description
The following examples are provided to explain the present invention in detail.
The invention may be embodied in the form of the following examples.
Example 1
In the specific implementation of the invention, external-use cinnamomum cassia presl essential oil for treating dysmenorrhea is prepared by dissolving and uniformly mixing 6mL of cinnamomum cassia presl essential oil, 6mL of evodia rutaecarpa essential oil, 6mL of dried ginger essential oil, 5mL of angelica essential oil, 6mL of nutgrass galingale rhizome essential oil, 5mL of fennel essential oil and 6g of borneol, wherein:
the cinnamon essential oil is prepared by crushing cinnamon into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Extracting a fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the weight-volume ratio refers to that the solid is counted by g, the liquid is counted by mL, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain cinnamon essential oil;
the evodia rutaecarpa essential oilPulverizing fructus evodiae into coarse powder which is sieved by a sieve of 10-20 meshes and carrying out supercritical CO treatment2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the evodia rutaecarpa essential oil;
the dried ginger essential oil is prepared by crushing dried ginger into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the dried ginger essential oil;
4ml of angelica essential oil is prepared by crushing angelica into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the angelica essential oil is obtained;
the rhizoma cyperi essential oil is prepared by crushing rhizoma cyperi into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Fluid extraction is carried out, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain the nutgrass galingale rhizome essential oil;
the fennel essential oil is prepared by crushing fennel into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2And (3) fluid extraction, wherein the weight-volume ratio of liquid to material is 1: 10-20, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so that the fennel essential oil is obtained.
Example 2
In the specific implementation of the invention, external cinnamon and dogwood essential oil for treating dysmenorrhea is prepared by dissolving and uniformly mixing 5.5mL of cinnamon essential oil, 6.5mL of fructus evodiae essential oil, 5.5mL of rhizoma zingiberis essential oil, 5.5mL of angelica essential oil, 5.5mL of rhizoma cyperi essential oil, 4.5mL of fennel essential oil and 6.5g of borneol, and the preparation method is the same as that of example 1.
Example 3
In the specific implementation of the invention, external cinnamon and dogwood essential oil for treating dysmenorrhea is prepared by dissolving and uniformly mixing 6.5mL of cinnamon essential oil, 5.5mL of fructus evodiae essential oil, 6.5mL of rhizoma zingiberis essential oil, 4.5mL of angelica essential oil, 6.5mL of rhizoma cyperi essential oil, 5.5mL of fennel essential oil and 5.5g of borneol, and the preparation method is the same as that of example 1.
Dysmenorrhea is also called "abdominal pain during menstruation", and is caused by aversion to cold or cold food or feeling of cold pathogen, emotional disorder, and asthenia, which are closely related to qi stagnation, cold accumulation, and blood stasis, resulting in stasis in uterus, and stagnation of qi and blood, resulting in pain. Cinnamon used in the cinnamon-dogwood essential oil is pungent, sweet and hot, can dispel cold and relieve pain, can disperse cold and dredge blood vessels, is used for amenorrhea due to stasis and dysmenorrhea caused by cold blood system, and evodia is pungent and bitter in flavor and loosens, is an essential medicine for treating pain caused by qi stagnation, and is a monarch medicine; dang Gui is indicated for regulating menstruation and alleviating pain, and is usually indicated for irregular menstruation and dysmenorrhea due to blood deficiency, congealing cold and blood stasis; the rhizoma cyperi has the effects of soothing the liver, regulating qi, regulating menstruation and relieving pain, is both the key medicines for regulating menstruation of gynecology, is used for treating dysmenorrheal caused by cold deficiency of thoroughfare and conception vessels and blood stasis blockage, and is a ministerial medicine; fennel fruit is used for dispelling cold and relieving pain, is used for treating hernia of cold, abdominal psychroalgia, dysmenorrheal and the like, is used for tonifying fire and supporting yang by dried ginger, dispelling cold and relieving pain, is used for treating amenorrhea due to stasis and dysmenorrheal caused by cold blood system, and is used as an adjuvant drug; borneol has the effects of inducing resuscitation, refreshing mind and relieving pain, and is used as a guiding drug to strengthen the efficacy of the drug. The medicines are combined to play the roles of dispelling cold, relieving pain, activating blood and dissolving stasis.
The invention has scientific and reasonable compatibility, mutual support of components, effective treatment of dysmenorrhea and very good experimental effect, and the related data are as follows:
1 Material
1.1 animals
ICR mice, SPF grade, female, 18-22g, 70. License number: SCXK (Lu) 2014-. Quality certification of experimental animals: no. 37009200018682. Provided by experimental animals center, Shandong province. Laboratory license number: SYXK 2015-.
1.2 drugs and reagents
The product of the embodiment 1 of the invention; motherwort particles, sunflower pharmacy, batch number: 170704, national standard Z13020088; oxytocin injection, Hangzhou animal medicine factory,batch number: 180418, veterinary approval article No.: veterinary medicine word (2013) 110201571; estradiol benzoate injection, hangzhou animal drug factory, batch number: 170519, veterinary approval article No.: veterinary medicine word (2013) 110202511; formaldehyde solution (analytically pure), dual chemical limited, cigarette end, batch number: 20180101, respectively; physiological saline, Shandongdu pharmaceutical Co., Ltd., batch No.: 11B 18081409; prostaglandin E2（PGE2) Kits (batch: 20190403A), prostaglandin F2 α (PGF 2 α) kits (batch: 20190403A), were purchased from BIO-RAD, USA.
1.3 instruments
Electronic balance, Oghas (Shanghai), (model: AR 1140/C);
a high-speed refrigerated centrifuge, Hunan instruments laboratory development Co., Ltd. (model: KDC-160 HR); an enzyme-labeling instrument: BioTek (USA) Inc. (model: CYT3 MFVDG);
a full-automatic rapid sample grinding instrument, Shanghai Jingxin industry development Limited (model: JXFSIPRP-48).
2 method
2.1 Molding and administration
Taking 50 ICR mice, all females, with weight of 18-21g, adaptively feeding for 3 days, randomly selecting 10 mice without molding, setting as blank group, and injecting estradiol benzoate (10 mg. kg) subcutaneously into the rest mice-1，2mg·mL-1) The model of dysmenorrhea is prepared by performing subcutaneous injection on times every day for 7 times, allowing mice to drink water and eat freely in the whole process, grouping and administering on the 6 th day after molding, randomly dividing the mice into 4 groups according to the weight of the mice, wherein each group comprises 10 mice, namely a model control group, a positive control group, a large dose group of the cinnamon-dogwood essential oil and a small dose group of the cinnamon-dogwood essential oil, a blank group is not treated, the abdomen of the model group is coated with 0.5mL of physiological saline, the positive control group is intragastrically administered with 0.2mL/10g of motherwort particles (7.5 g/kg), the large dose group of the cinnamon-dogwood essential oil and the small dose group of the cinnamon-dogwood essential oil are respectively coated with the abdomen essential oil, the large dose is 0.2 mL/only ( times after 2 hours), and the small dose is 0.2 mL/only daily administered for 2 days.
2.2 detection index and detection method
2.2.1 behavioral indicator detection
The mice in each group are subjected to abdominal cavity injection oxytocin (2U/mouse) for writhing experiment determination after 12h fasting before the 2 nd administration and 30min after the last administration, the writhing time of the th time and the writhing times in 15min are recorded, the writhing reaction standard is that the hind limb and the trunk of the mice extend, the abdomen contracts inwards, and the lateral limb and the hip internally rotate to react.
2.2.2 Biochemical index detection
Within two hours after the torsion test is finished, blood is taken from eyeballs of mice of each group, the mice are placed at room temperature for 30min and then centrifuged at 3500r/min for 10min, then the uterus is dissected, half-added 9 times of ice physiological saline is taken for homogenate, the centrifugation at 3500r/min for 10min is carried out, homogenate supernatant is separated, and prostaglandin E2 (PGE 2) and prostaglandin F2 α (PGF 2 α) are detected according to the operation steps of an Elisa kit.
3 statistical processing method
The data in the experiment are processed by excel and expressed as ('x +/-s),' one-factor variance analysis is adopted for comparison among groups, the Least Significant Difference (LSD) method is adopted for variance check, the Games-Howell method is adopted for variance check, and the radius method is adopted for grade data check. P <0.05, with differences of P <0.01 statistically significant.
Results of the experiment
4.1 influence on writhing latency and writhing frequency of oxytocin-induced dysmenorrheal mouse model
Table 1: influence of cinnamon essential oil on torsion latency and torsion times of oxytocin-induced dysmenorrheal model of mice (X +/-S, n =10)
| Grouping | Dosage form | Number of times of body twisting | Incubation period |
| Blank group | ----- | 0±0 | 0±0 |
| Model set | 0.5 ml/piece | 22±13.08 | 40.2±30.56 |
| Motherwort granule group | 0.15g/10g | 12.1±5.09 | 176±130.53 |
| Macro-dose group of cinnamon and dogwood essential oil | 0.5 ml/piece | 5.7±4.14 | 371.9±300.11 |
| Small dose group of cinnamon and dogwood essential oil | 0.25 ml/piece | 5.9±5.45 | 256.5±136.68 |
Comparison with blank group▲▲P is less than 0.01; comparison with model group**P＜0.01
4.2 Effect on PGE2 and PGF2 α levels in dysmenorrhea mouse uterine homogenates
TABLE 3 Effect of Osmanthus fragrans chamomilla essential oil on PGE2 and PGF2 α levels in uterine homogenates of mouse dysmenorrheal model caused by oxytocin (` X + -S, n =10)
Note: comparison with blank group▲▲P is less than 0.01; comparison with model group*P＜0.05，**P＜0.01
5 small knot
The experiment invention shows that the cinnamon twig essential oil and the cinnamon twig essential oil can obviously reduce the twisting frequency of a dysmenorrheal model mouse caused by estradiol benzoate, obviously prolong the twisting latency period, compared with a blank group, the content of PGE2 in uterine homogenate of the model group is obviously reduced, the content of PGF2 α is obviously increased, and the value of PGF2 α/PGE2 is obviously increased.
Second, clinical trial
Under the condition of ensuring safety in animal experiments, clinical trials prove that the effect is very good, and the related data are as follows:
all 15 selected dysmenorrhea patients were primary dysmenorrhea (excluding secondary dysmenorrhea samples, such as those caused by pelvic infection, adenomyosis, cervical stenosis, endometriosis, etc.). Age 17-25 years, unbelided young girls. The menstrual cycle is regular for 28-35 days, no history of abdominal trauma, waist trauma and pelvic inflammatory disease exists, and the time of dysmenorrhea is from a few hours before menstruation to 2-3 days after menstruation. B-ultrasonic examination, no pelvic organ disease.
Applying the essential oil of fructus Corni 1-2 days before menstruation to lower abdomen at a dosage of 0.2mL/cm2After 2 hours, times of application are carried out to ensure that the ambient temperature is about 30 ℃.
The curative effect standard is as follows: and (3) healing: the pain is completely eliminated, and the effect is obvious: the pain is obviously relieved (70 percent), and the effect is as follows: pain was reduced (≧ 40%), not: the pain did not improve at all.
Statistical treatment results: 5 cases are cured, 7 cases are obviously effective, 3 cases are effective, 0 case is ineffective, and the total effective rate is 100%.
The invention has the advantages of simple preparation method, rich raw materials, easy production and preparation, and definite curative effect, has the function of relieving pain, is effectively used for treating the dysmenorrheal, is an innovation on medicaments for treating the dysmenorrheal, and has obvious economic and social benefits.
Claims (4)
1, external essential oil of cinnamomum cassia presl for treating dysmenorrhea, which is characterized by being prepared by dissolving and uniformly mixing 5-7mL of cinnamon essential oil, 5-7mL of evodia rutaecarpa essential oil, 5-7mL of dried ginger essential oil, 4-6mL of angelica essential oil, 5-7mL of nutgrass galingale rhizome essential oil, 4-6mL of fennel essential oil and 5-7g of borneol as raw materials, wherein:
the cinnamon essential oil is prepared by crushing cinnamon into coarse powder which is sieved by a sieve of 10-20 meshes and supercritical CO2Extracting a fluid, wherein the weight-volume ratio of liquid to material is 1: 10-20, the weight-volume ratio refers to that the solid is counted by g, the liquid is counted by mL, the extraction temperature is 42-50 ℃, the extraction pressure is 20-25 MPa, the separation temperature is 50-60 ℃, the separation pressure is 4.5-5.5 MPa, and the extraction time is 1.5-2.5 h, so as to obtain cinnamon essential oil;
the preparation methods of the evodia essential oil, the dried ginger essential oil, the angelica essential oil, the rhizoma cyperi essential oil and the fennel essential oil are the same as those of the cinnamon essential oil.
2. The external essential oil of cinnamomum cassia presl for treating dysmenorrhea according to claim 1, which is prepared from the following raw materials: 6mL of cinnamon essential oil, 6mL of fructus evodiae essential oil, 6mL of rhizoma zingiberis essential oil, 5mL of angelica essential oil, 6mL of rhizoma cyperi essential oil, 5mL of fennel essential oil and 6g of borneol are dissolved and mixed uniformly to prepare the traditional Chinese medicine.
3. The external essential oil of cinnamomum cassia presl for treating dysmenorrhea according to claim 1, which is prepared from the following raw materials: 5.5mL of cinnamon essential oil, 6.5mL of fructus evodiae essential oil, 5.5mL of rhizoma zingiberis essential oil, 5.5mL of angelica essential oil, 5.5mL of rhizoma cyperi essential oil, 4.5mL of fennel essential oil and 6.5g of borneol.
4. The external essential oil of cinnamomum cassia presl for treating dysmenorrhea according to claim 1, which is prepared from the following raw materials: 6.5mL of cinnamon essential oil, 5.5mL of fructus evodiae essential oil, 6.5mL of rhizoma zingiberis essential oil, 4.5mL of angelica essential oil, 6.5mL of rhizoma cyperi essential oil, 5.5mL of fennel essential oil and 5.5g of borneol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911275190.7A CN110732016A (en) | 2019-12-12 | 2019-12-12 | A topical essential oil of fructus Cinnamomi Immaturus for treating dysmenorrhea |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911275190.7A CN110732016A (en) | 2019-12-12 | 2019-12-12 | A topical essential oil of fructus Cinnamomi Immaturus for treating dysmenorrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110732016A true CN110732016A (en) | 2020-01-31 |
Family
ID=69274607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911275190.7A Pending CN110732016A (en) | 2019-12-12 | 2019-12-12 | A topical essential oil of fructus Cinnamomi Immaturus for treating dysmenorrhea |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110732016A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546088A (en) * | 2003-12-02 | 2004-11-17 | 胡惠平 | Dysmenorrhea treating Chinese traditional medicine preparation |
| CN102178922A (en) * | 2011-05-04 | 2011-09-14 | 张爱霞 | Traditional Chinese medicine composition for treating dysmenorrhea and preparation method thereof |
| CN102397376A (en) * | 2011-09-29 | 2012-04-04 | 上海中医药大学 | Chinese medicinal composition for treating dysmenorrhea and compound supercritical fluid extract |
-
2019
- 2019-12-12 CN CN201911275190.7A patent/CN110732016A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1546088A (en) * | 2003-12-02 | 2004-11-17 | 胡惠平 | Dysmenorrhea treating Chinese traditional medicine preparation |
| CN102178922A (en) * | 2011-05-04 | 2011-09-14 | 张爱霞 | Traditional Chinese medicine composition for treating dysmenorrhea and preparation method thereof |
| CN102397376A (en) * | 2011-09-29 | 2012-04-04 | 上海中医药大学 | Chinese medicinal composition for treating dysmenorrhea and compound supercritical fluid extract |
Non-Patent Citations (3)
| Title |
|---|
| 代桂满，靳红微，秦军: "敷脐法在妇科病中的应用", 《河北中医》 * |
| 陶御风: "《临证本草 修订本》", 31 May 2016, 中国医药科技出版社 * |
| 韦红，等: "中药敷脐疗法治验举隅", 《湖北中医杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103721131B (en) | A kind of Chinese medicine suppository and its preparation method treating women's chronic pelvic inflammatory disease | |
| WO2006076844A1 (en) | Traditional chinese medicament for treating injuries from falls, rheumatism and ostealgia and method for manufacture thereof | |
| CN113398078B (en) | Granular traditional Chinese medicine for improving ovarian reserve function and preparation method thereof | |
| CN105943651B (en) | A kind of Chinese medicine composition that treating premature ovarian failure and its application | |
| CN107669991A (en) | A kind of pharmaceutical composition for reducing serum uric acid level and preparation method thereof | |
| CN104147388B (en) | Traditional Chinese medicine composition for treating migraine and preparation method thereof | |
| CN110732016A (en) | A topical essential oil of fructus Cinnamomi Immaturus for treating dysmenorrhea | |
| CN111494482B (en) | Traditional Chinese medicine composition for preventing and treating spring colds and preparation and application thereof | |
| CN116173177A (en) | Pharmaceutical composition for continuously improving male sexual function and preparation method thereof | |
| CN100546617C (en) | A kind of Chinese medicine preparation for the treatment of oviduct obstructive sterility | |
| CN103784541A (en) | Traditional Chinese medicine for treating pains on neck, shoulders, waist and legs | |
| CN104587304B (en) | A kind of medicine for the treatment of Simple Obesity and uses thereof | |
| CN105749153A (en) | Medicine composition for treating liver-depression kidney-deficiency premature ovarian failure | |
| CN105434739A (en) | Traditional Chinese medicine composition for treating chalazia and preparation method thereof | |
| CN101590114B (en) | Medicament for treating multiple sclerosis and preparation method thereof | |
| CN110841051A (en) | External-use ginger and white-cord essential oil for treating migraine | |
| CN112076271B (en) | Traditional Chinese medicine composition for clearing heat and promoting diuresis and preparation method and application thereof | |
| CN116688058B (en) | Li medicine for impotence, preparation method and application thereof | |
| CN111494446B (en) | Traditional Chinese medicine composition for treating biliary colic and application thereof | |
| CN108310169A (en) | Pharmaceutical composition and preparation method thereof for preventing osteoarthritis | |
| CN110507763A (en) | A kind of Chinese herbal medicine oral tablet and preparation method thereof preventing and treating a variety of lymthomas | |
| CN106075027B (en) | A kind of Chinese medicine composition for treating the proliferation of mammary gland | |
| CN105597020A (en) | Pharmaceutical composition for treating polycystic ovarian syndrome combined with mammary gland hyperplasia | |
| CN105288344A (en) | Traditional Chinese medicinal composition for treating liver and gall calculi, and application thereof | |
| CN110898204A (en) | External-use Huanggui medicinal essential oil for treating postoperative abdominal distension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200131 |